Background. Several treatments for alcohol dependence have been tested in randomized controlled trials, giving rise to systematic reviews with a network of evidence structure, or mixed treatment comparisons (MTCs). Within the network, there are few direct comparisons of active treatments. Thus far, this network has not been adequately analyzed. For example, ''indirect comparisons'' between treatments (e.g., the comparison of treatments B:C obtained via estimates from A:B and A:C trials) have not been incorporated into estimates of treatment effects. This has implications for the planning of future randomized controlled trials. Methods. We applied recent developments in Bayesian MTC meta-analysis to analyze the network of evidence. Using these results, we proposed a methodology to inform, design, and power a hypothetical trial in the context of an updated meta-analysis for treatments that have been infrequently compared and therefore whose effect sizes are not well informed by a meta-analysis. Results. An MTC metaanalysis provides more accurate estimates than a pairwise meta-analysis and uncovers decisive differences between active treatments that have been infrequently directly compared. Weighting across all outcomes indicates that a combination (naltrexone 1 acamprosate) treatment has the highest posterior probability of being the ''best'' treatment. If a new clinical trial were to be conducted of a combination therapy versus acamprosate alone, there is no feasible sample size that would result in a decisive meta-analysis. Conclusions. An MTC meta-analysis should be used to estimate treatment effects in networks in which direct and indirect evidence are consistent and to inform the design of future studies.
A lcohol dependence is an important health risk factor that can lead to disability and death. Alcohol consumption is potentially avoidable, and effective strategies to help people who are dependent on alcohol to reduce excessive drinking and maintain abstinence following detoxification are needed. Several treatments have been tested in randomized controlled trials (RCTs) with various comparators of interest; thus, evidence synthesis strategies are needed for both decision making and planning new research studies based on the existing body of RCT literature.
The clinical practice guidelines that inform medical decision making should rely on evidence-based evaluations of treatment options, primarily systematic reviews of RCTs. 1 Several systematic reviews of RCTs for pharmacological treatments for alcohol dependence have been conducted. [2] [3] [4] [5] [6] Very recently, 2 systematic reviews were published in the Cochrane database, 7, 8 which represent the pinnacle of evidence synthesis. Cochrane reviews naturally give rise to a mixed treatment network of evidence structure (more technically termed an incomplete randomized block design of trials). Within a network, ''direct evidence'' refers to evidence about 2 treatments that have been directly compared (e.g., A:B), while ''indirect evidence'' refers to evidence about 2 treatments obtained from comparisons via a common comparator (e.g., evidence for A:B derived from A:C and B:C trials). 9 There is a growing body of literature termed ''mixed treatment comparison'' (MTC) meta-analysis [10] [11] [12] [13] [14] [15] [16] or ''network metaanalysis'' in which the objective is to combine all available evidence into an internally consistent set of estimates while respecting randomization. The role of MTC synthesis is particularly clear in medical decision making in which a choice must be made on which of several treatments to adopt in national treatment recommendations, which treatments to further study, and how to design those studies.
The goal of this article was to assimilate the existing network of evidence using Bayesian MTC methods and, based on the findings, outline a methodology that could be followed to design a new trial. We first assess the assumptions of MTC, such as evidence consistency across direct and indirect comparisons. [17] [18] [19] We then report and compare the resulting MTC estimates with those obtained from pairwise meta-analyses and demonstrate improved efficiency of the MTC estimates. We present an overall ranking system weighted across the 4 outcomes of interest to arrive at the ''best'' treatment. Finally, we use predictions from the Bayesian MTC model in a novel way to guide the planning of a hypothetical trial for treatments infrequently directly compared that takes into account the entire existing network of evidence.
METHODS

Data
Two Cochrane database systematic reviews of naltrexone (NAL) and acamprosate (ACA) have been performed and updated as of 2008 7 and 2011, 8 respectively. Figure 1 shows the RCT network structure. The bracketed number represents the number of trials reporting each outcome as extracted from the Cochrane database for the return to drinking outcome only. The network demonstrates that all direct comparisons have been studied but that NAL and ACA have only been directly compared 3 times, and their combination has only been directly compared to placebo twice. For additional information, the reader is referred to Table 1 in the supplementary material, which presents summary data from each trial in the multiarm network. Given that there are only 3 direct comparisons of ACA versus NAL in the literature, results for this comparison have been equivocal; that is, neither treatment has been shown via pairwise meta-analysis to be superior. In addition, given only 2 direct comparisons of combined NAL 1 ACA with any treatment, no significant effects have been found. Since few studies consider direct comparisons of active treatments, it is essential that meta-analyses incorporate the plethora of indirect comparisons.
MTC Model
We performed a random-effects MTC metaanalysis for the RCTs reported in the Cochrane database. All outcomes were modeled independently (univariately). We used a Bayesian hierarchical framework to model 3 binary outcomes, relapse, return to drinking, and discontinuation (R, RD, and D, respectively), and 1 continuous outcome, percentage of days abstinent (PDA). We used the odds ratio (OR) to summarize the binary outcomes R, RD, and D and mean differences to summarize the PDA.
For the binary model, let the total number of events in the ith study for intervention k be denoted by y ik and the corresponding number of patients be denoted by n ik . The probability of an event (p ik ) is given based on the observed number of events in each study arm. We used the logistic regression difference parameterization of Lu and Ades 17 in which each study i is assigned a reference intervention arm b, and the corresponding log odds for that intervention is denoted by m ib . The parameter d ibk denotes the ith trial log OR for intervention k relative to intervention b, where d ibk is assumed to be normally distributed with pooled mean treatment effect d bk and common (homogeneous) variance, s 2 . The OR model can be expressed as
where p ik is the probability of an event in trial i under treatment k. Taking treatment A as the overall MTC baseline, all relative treatment effects can be written in terms of the following basic parameters, which define the consistency equations 17 :
We estimated the posterior densities of the parameters of interest using Markov chain Monte Carlo (MCMC) methods implemented in freely available WinBUGS software. 19, 20 We adapted the WinBUGS code of Dias and others 21, 22 (program 1c for binary outcomes and 5a for normal outcomes). We specified vague prior distributions for all the parameters, allowing the data to drive inference. Specifically, we assigned each m i and d i to be N(0,10000), which are essentially quite vague, although proper. For the log OR model, we assigned the common standard deviation, s, a uniform (0,5) prior, which is assumed to be the same for all pairwise comparisons. This prior distribution provides the appropriate weight to the possibility of small or zero variance. For the continuous outcome (PDA), we used the specification of program 5a, 22,23 with a normal likelihood, identity link, and normal random effects (we refer the reader to the original article for the model setup). We specified the prior distribution for between-trial variance as a uniform (0,10). For each outcome, we also graphically assessed model sensitivity to other prior distributions.
MTC Model Evaluation
To assess model convergence, we used trace plots and the Brooks-Gelman-Rubin statistic. For each analysis, we ran 2 chains, each employing 40,000 burn-in iterations and monitoring an additional 40,000 iterations, basing posterior inference on every second sample to reduce autocorrelation in the sample. Thinning was chosen based on the observation of autocorrelation plots with the goal of minimizing autocorrelation in the resulting chain.
When carrying out an MTC meta-analysis, it is essential to first check the consistency of direct and indirect sources of evidence using a hypothesis testing framework. We assessed consistency based on both ''node splitting'' and the deviance information criteria (DIC). 18, 24 Node splitting separates evidence available for a particular treatment comparison (i.e., node in a directed acyclical graph) into ''direct'' and ''indirect,'' 18 and the conflict between direct and indirect evidence sources is measured by comparing their posterior distributions. Using the methods of Dias and others, 18 we obtained the posterior mean treatment effect d A;B dir from the pairwise meta-analysis of the trials comparing A and B directly and obtained d A;B indir from the MTC meta-analysis of Return to drinking (2) Relapse (2) % Days Abstinent (1) Discontinuation (2) Return to drinking (2) Relapse (2) % Days Abstinent (1) Discontinuation (2) NAL+ACA ACA
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Return to drinking (24) Relapse (6) % Days Abstinent (19) Discontinuation (20) Return to drinking (3) Relapse (3) % Days Abstinent (2) Discontinuation (3) Return to drinking (13) Relapse (10) % Days Abstinent (7) Discontinuation (19) Return to drinking (2) Relapse (2) % Days Abstinent (1) Discontinuation (2) the remaining studies (i.e., trials including A and C and trials including B and C). Note that the underlying model of node splitting is the same as the model presented in the Methods section, except that the trial-specific log odds ratio (OR) d A;B is assumed to be drawn from Nðd A;B dir ; s 2 Þ and Nðd A;B indir ; s 2 Þ for direct and indirect evidence, respectively. We then examined the posterior distribution of the inconsistency parameter, v A;
indir , to determine whether the data satisfy the evidence consistency null hypothesis, H0 :
indir (i.e., that direct and indirect effect sizes arise from the same distribution). This is accomplished by fitting the model and using MCMC results to compute the proportion (prob) of times v X; Y > 0 in the sample. The reported P value for the hypothesis test of evidence consistency obtained by node splitting is P = 2 3 min(prob,1 -prob). As a second evidence consistency check, we compared the DIC resulting from the full MTC model to that resulting from the nodesplitting models; reduced DIC for the node-splitting model signify a potential inconsistency between the direct and indirect sources of evidence for that node. Although DIC has no meaningful scale, differences of 5 to 10 (smaller is better) signal an improvement in fit, and this is how we interpreted model comparisons in this article. 24 For each outcome, we also compared Bayesian MTC meta-analysis posterior mean effects and 95% credible intervals (CIs) with those from Bayesian random-effects pairwise meta-analyses of head-to-head (direct) comparisons. For the outcomes R, RD, and D, all results are presented in terms of posterior OR (95% CI), where a value . 1 indicates a worse outcome. For the PDA, results are reported in terms of posterior mean difference (95% CI). In general, a decisive or ''significant'' effect corresponds to the 95% CI excluding 1 for ORs and 0 for mean differences. As in Ades and others, 25 we report the standard deviation (s) and its 95% CI, the posterior mean residual deviance, the effective number of parameters, and the DIC for each MTC model.
Planning a New Trial
The effect size used to generate the sample size for new trials is typically derived from observed effect sizes from previous clinical or preclinical trials or, at best, from a reported meta-analysis. This effect size is then used to power the trial in isolation of accumulated evidence. However, the empirical distribution of observed meta-analysis effect sizes should not be used to plan future trials since this distribution is overdispersed. New research suggests that basing the sample size of a future trial on the results of an updated meta-analysis that will include it is more sensible than powering a future trial in isolation. 26 Posterior distributions of effect sizes and posterior predictive distributions for a new observation are natural consequences of Bayesian estimation and sensible tools on which to base future studies. A predictive effect size, d bkðnewÞ , can be generated and given a fixed baseline group effect size, used to generate a new observation, y ikðnewÞ , from a fixed sample size. However, no closed form expression for this distribution exists, and hence, sampling from it within a simulation framework such as that offered by Bayesian MCMC methods would appear to be the most straightforward.
We applied the following approach in the MTC meta-analytic setting adapted from Dias and others 21 for planning a 2-arm RCT with equal patient allocation and binary outcomes based on ORs, and testing H 0 : d bk ¼ 0 versus H 1 : d bk is not equal to 0: 
RESULTS
MTC Model Evaluation
The exact P values for the test of the null hypothesis of evidence consistency formulated by nodesplitting comparisons of direct and indirect evidence, as well as node-splitting and full-model DIC, are reported in Table 1 . All hypothesis tests of evidence consistency are nonsignificant at the .05 a level, indicating consistent directionality of evidence and therefore the appropriateness of an MTC meta-analysis for this network. Further, the DIC reported for the full MTC model are consistently lower than those reported from the node-splitting model, providing additional evidence of consistency. 18 Table 1 also shows that for the binary outcomes, the posterior mean standard deviation is moderately sized (range = 0.25-0.43) and different from zero for all 3 binary outcomes but within an expected range as per previous reports. 25 For the continuous outcome PDA, the posterior mean standard deviation is also moderately sized. Global goodness-offit tests including posterior mean of the residual deviance, DIC, and effective degrees of freedom are also reported in Table 1 . Figure 2 shows that the posterior mean estimate of s for a range of uniform priors remains unchanged for the log OR model and also remains unchanged for the upper bound !10 for the continuous model. Thus, we used a prior distribution of uniform (0,10) for the continuous outcome. Figure 3 presents results of the pairwise metaanalysis of head-to-head trials (left) and the MTC meta-analysis (right) for all possible treatment comparisons. The MTC and pairwise results are directionally similar, which is expected given confirmed evidence consistency. However, for infrequently compared active treatments, 95% CIs are much narrower for the MTC model. The MTC model clearly benefits from greater precision since common comparator information available from the network of evidence is utilized to improve estimates.
MTC Meta-analysis Results
Of primary interest is how ACA compares to NAL since only 3 direct comparisons of these treatments have been performed, resulting in not statistically significant pairwise meta-analytic findings. From the MTC meta-analysis, ACA increases the odds of R versus NAL (OR = 1.64; 95% CI = 1.10-2.56). This effect previously was not found to be significant, although it was in the same direction. 7, 8 Similarly, ACA increases the PDA over NAL (mean difference = 7.14; 95% CI = 4.13-10.11), which was also not previously detected as significant in the pairwise meta-analysis. These findings are consistent with the clinical literature, which posits NAL as a treatment for R and ACA for themaintenance of abstinence. 27 Thus, an MTC analysis confirms that these treatments appear to have beneficial effects on different aspects of drinking behavior. Figure 3 also indicates that combined NAL 1 ACA versus placebo reduces the odds of RD (OR = 0.42; 95% CI = 0.16-0.84). While this is a greater estimated effect size than either NAL or ACA versus placebo, MTC results indicate that a combination treatment is not better than either NAL or ACA alone; however, a combination treatment has rarely been directly compared with active treatments.
The posterior probabilities of being among the kth best treatments are presented as rankograms in Figure  4 . 25 The 4 panels show the probability of being the first, second, third, and fourth best treatment for each outcome. While these estimates should not be interpreted conclusively (because they are close in value due to the considerable uncertainty in inference about relative treatment effects, as demonstrated in Figure 3 ), they are potentially informative for deciding which treatments to further study. It is notable that the placebo is never the best treatment. Naltrexone appears to be superior for reducing the odds of R (mean probability of being the best = 0.59), while ACA appears to be superior for the PDA (mean probability of being the best = 0.82). With respect to D, all treatment groups appear to be equivalent. We further estimated a weighted rank across the 4 outcomes using an equal weighting scheme in the absence of prior information as to which outcome is more important (0.25 for each outcome). The posterior probability of being the best treatment is 0, 0.35, 0.24, and 0.41 for placebo, ACA, NAL, and NAL 1 ACA, respectively. Although the MTC meta-analysis is able to provide decisive estimates of treatment effects when the pairwise meta-analysis cannot, the posterior rankings for the 3 active treatments are still inconclusive.
Planning a New Trial
There is some indication by the weighted (omnibus) posterior rankings that the treatment combination of NAL 1 ACA has the highest posterior probability of being the best treatment. This finding is driven by the outcomes R and RD. However, decisive effects of the combination treatment versus ACA alone are not detected by an MTC meta-analysis (OR = 0.81; 95% CI = 0.31-1.58 for RD and OR = 0.69; 95% CI = 0.32-1.14 for R); however, few head-to-head trials of combined therapy with any comparator exist. A decisive effect is also not detected in a pairwise meta-analysis, a result based on only 2 head-to-head trials (Figure 1) . Specifically, 1 of these head-to-head trials did not 27 and 1 trial did 28 show a significant effect of combined therapy over ACA monotherapy. Importantly, the trial that did not show significance was 10 times larger than the one that did; thus, it provides the majority of the weight in a meta-analysis. Figure 4 Treatment rankings: probability that each treatment is the kth best (k = 1, 2, 3, 4) on reducing relapse, return to drinking, discontinuation, and increasing percentage of days abstinent.
Given the equivocal results in light of very little direct evidence for this comparison, subject matter researchers might still question whether there is any benefit of the treatment combination over ACA. In fact, studies are currently underway to detect such effects. 29, 30 As a result, we planned a hypothetical new 2-arm trial for R and RD powered in the context of an updated MTC meta-analysis to further investigate these interventions. Since most RCTs favor the 2-arm approach, we considered this case for ease of presentation, although the approach easily could be extended to any number of treatment arms. The following serves as an example of how such a study might be planned.
For the outcomes R and RD, we obtained predictive estimates for the effect size (log OR), d NAL 1 ACA:ACA(new) , where the event rate of ACA (the reference group) is assumed known from the 24 placebo-controlled trials of ACA (Figure 1) . The distribution of 1000 sampled predictive effect sizes for the outcomes is shown in Figure 5 . Following the methodology outlined in the Methods section, Figure  6 shows the power curve for the hypothetical trial designed in 2 ways: 1) in isolation, as a single new clinical trial that is not part of the network of evidence; and 2) in the context of the network of evidence presented in Figure 1 meta-analysis. Designing this trial in isolation requires a feasible sample size to obtain 80% power to detect a significant effect on either outcome; however, obtaining 80% power to detect a decisive effect in a new MTC meta-analysis is infeasible, as the power curve asymptotes at approximately 0.60 and 0.18 for R and RD, respectively, for any reasonable sample size. The reason for this is that irrespective of the size of the new study, its influence in a random-effects meta-analysis is limited by the degree of heterogeneity in the analysis. In fact, the sample size directly depends on the amount of heterogeneity in the existing network of trials, as the weight of the ith study in a classic random-effects meta-analysis is
is the estimated variance of the effect size in the ith (i.e., new) study. 26 In our MTC meta-analysis, the posterior estimate of s 2 is moderately large (Table 1) , which means that the contribution of the new study is proportionally downweighted. The result is that designing a trial in isolation using the observed random-effects meta-analytic effect size will underestimate the size of the trial that needs to be conducted to add to the existing network of evidence. This process was repeated by breaking up the new study into several smaller studies. While power improves slightly, 80% power is still not achieved.
DISCUSSION
Mixed treatment evidence structures are more common than pairwise structures, 17 and research supports refining evidence synthesis by incorporating both direct and indirect treatment comparisons to better inform health care decisions. 9, 16, 17, 31, 32 The role of MTC synthesis is particularly clear in medical decision making in which a choice must be made on which of several treatments to adopt in national treatment recommendations as well as which treatments to further study and how to design those studies. We have shown that consistency of evidence is established for treatments for alcohol dependence, which indicates that a relatively homogeneous internal structure exists. We have shown that utilizing MTC evidence allows for the detection of significant effects for treatments that are infrequently directly compared (e.g., ACA v. NAL and NAL 1 ACA v. placebo), tighter CIs when indirect effects are exploited, and posterior rank ordering of treatments.
The results of our analysis can assist planning and decision making by determining which treatment comparisons lack direct and/or indirect evidence and need to be further compared. Specifically, this is achieved by determining effect sizes from a new trial using posterior or posterior predictive estimates from an MTC meta-analysis and then designing the trial in the context of a new MTC meta-analysis. We have presented the methodology for using Bayesian MTC meta-analysis results to determine which treatments should be further studied, for generating predicted clinical trial data, and for powering the new study in the context of refitting the meta-analysis. The simulations show that the power for designing a trial in isolation versus in the context of a meta-analysis can be dramatically different and depends both on the number of direct comparisons and betweentrial heterogeneity.
Although we did not pursue it in this article, the value of information may also be used to design and prioritize future trials. 33 This methodology involves evaluating the likelihood that the decision will change following the new study as well as the net benefit in performing the new study. These quantities of interest depend on the source of variation in the current meta-analysis and the predictive heterogeneity. Greater certainty and smaller study bias result in a larger value of information. The value of information can be evaluated for a range of different types of studies, for example, multiarm and multicenter, to prioritize the RCT to be conducted next. Our approach easily could be extended to designing a study for any number of treatment arms, which is a scenario of importance due to the difficulty of such designs. In general, when planning a .2-arm clinical trial, identifying a priori the correlation structure between several treatment effects can be difficult. In the context of a heterogeneous MTC model for multiarm networks of evidence, the correlation among treatment groups within a study would be propagated through the Bayesian MTC meta-analytic model to the posterior predictive estimates of effect size for a new study; thus, this correlation structure would inherently be taken into account when designing the new study.
Limitations of the current study along with further research directions must be addressed. First, our analysis of several outcomes likely inflates the type I error rate. Rather than enforcing a strict correction for multiple comparisons, this could be addressed in future research via a multivariate MTC metaanalysis, which would help control the type I error rate by exploiting the correlation in outcomes and by borrowing information in light of missing outcomes. Second, while NAL decreases R and ACA improves the PDA, which is consistent with their biochemical nature, when taking all 4 outcomes into consideration simultaneously, there is no consensus as to which treatment is best.
